reports
- Carole Braudeau
- Carole Braudeau
- Research Department
IBERIAN DAILY 26 AUGUST (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: ENAGÁS. Euro STOXX 50 stays above 5,400 European stock markets closed with losses of -0.8% in a session that ended worse than it began. In the STOXX 600, most sectors (17/20) were in the red, with bond proxies like Construction and Utilities leading the way, hurt by the rise in long-term public debt curves, whereas Media and Financial Services ended with the biggest gains. On the macro side, in Germany August’s IFO rose more than expected, reaching a high over the past two years. ...
- Research Department
INFORME DIARIO 26 AGOSTO (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ENAGÁS. EUROPA: UNICREDIT. El Euro STOXX 50 conserva los 5.400 puntos Las bolsas europeas cerraron con caídas del -0,8% en una sesión de más a menos. En el STOXX 600 la mayoría de sectores presentaron caídas (17/20) dirigidas por bond proxies como Construcción y Utilities que se vieron perjudicados por el repunte de los tramos largos de la curva de deuda pública mientras que Media y S. Financieros se desmarcaron con las mayores subidas. Por el lado ...
- Jan Frederik Slijkerman
- Jeroen van den Broek
- Jesse Norcross
- Nadège Tillier
- Timothy Rahill
- Carole Braudeau
- Carole Braudeau
- Research Department
IBERIAN DAILY 22 AUGUST (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: IAG, TELEFÓNICA. Markets doubtful awaiting Powell in Jackson Hole European stock markets closed better than they opened, with some indices like the FTSE 100 managing to end with slight gains, whereas the DAX and IBEX ended practically flat. In the STOXX 600, the sectors rising the most were Energy, Banks and Basic Materials, with the biggest drops coming in Media, Consumer Goods and Chemicals. On the macro side, in the euro zone August’s preliminary manufacturing PMI rose more tha...
- Research Department
INFORME DIARIO 22 AGOSTO (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: IAG, TELEFÓNICA. EUROPA: AIR LIQUIDE. Mercados dubitativos a la espera de Powell en Jacson Hole Ayer las bolsas europeas fueron de menos a más y algunos índices como el FTSE 100 lograron terminar con ligeras ganancias mientras que el DAX y el Ibex terminaron casi sin cambios. En el STOXX 600 los sectores que más subieron fueron Energía, Bancos y R. Básicos frente a las mayores caídas de Media, B. Consumo y Químicas. Por el lado macro, en Eurozona el...
Sanofi: Information concerning the total number of voting rights and s...
Sanofi: Information concerning the total number of voting rights and shares - July 2025 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,454,937,946Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry unde...
Sanofi: Informations relatives au nombre de droits de vote et d'action...
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juillet 2025 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 454 937 946 euros Siège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris DateNombre d’actions composant le capital Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris actions...
Press Release: Sanofi’s rilzabrutinib earns orphan designation in the ...
Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025Additional orphan designation underscores Sanofi commitment to advancing new medicines in immune-mediated rare diseases Paris, August 14, 2025. The European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor, ...
Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignati...
Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4 Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4 Données de l’étude positive de phase 2 évaluant le rilzabrutinib pour le traitement de la maladie liée aux IgG4 présentée à l’EULAR de 2025Cette nouvelle désignation de médicament orphelin souligne l’engagement de Sanofi en faveur du développement de nouveaux médicaments contre les maladies rares à médiation immunitaire Paris, le 14 août 2025. ...
- Research Department
IBERIAN DAILY 12 AUGUST (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: ROVI, TALGO. A transition session awaiting the US inflation data It was a transition session with flat stock markets or with slight corrections and without practically any volume and macroeconomic references, awaiting the release of July’s inflation in the US today (main reference this week) amid some fears about a rise in inflation as tariffs are passed on to prices, which could delay the rate cuts expected in September in the US. Thus, in Europe in the STOXX 600 defensive sector...
- Research Department
INFORME DIARIO 12 AGOSTO (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ROVI, TALGO. Sesión de transición a la espera del dato de inflación americana Sesión de transición con bolsas planas o con ligeros retrocesos, sin apenas volumen negociado y sin referencias macro, a la espera de la publicación de la inflación de julio esta tarde en EE.UU. (principal referencia esta semana). Existe cierto temor a un repunte de inflación a medida que se empiezan a trasladar los aranceles a los precios finales, lo que podría volver a ...
- Research Department
IBERIAN DAILY 08 AUGUST (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: ENAGÁS. Stock markets near highs It was a positive session for European stock markets, which climbed >1.3% despite the implementation of tariffs. Even though it lagged behind Europe, the Ibex hit new highs. Thus, in the STOXX 600 all sectors except Energy, Telecom and Utilities ended with gain, led by Travel&Leisure and Chemicals. On the macro side, in the UK, as expected, the BoE cut rates by 25bps to 4.0% although with a tight vote (5 votes in favour vs. 4). In Germany, June’s i...
- Research Department
INFORME DIARIO 08 AGOSTO (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ENAGÁS. EUROPA: AIRBUS, MUNICH RE. Bolsas rumbo a máximos Jornada de números verdes en las bolsas europeas, que dispararon sus ganancias por encima del 1,3% a pesar de la entrada en vigor de los aranceles. El Ibex pese a estar a la cola de Europa, amplió su racha y sus máximos. Así, en el STOXX 600 todos los sectores menos Energía, Telecos y Utilities terminaron con ganancias, lideradas por Viajes&Ocio y Químicas. Por el lado macro, en R. Unido el B...
Viscofan Sa: 1 director
A director at Viscofan Sa sold 7,400 shares at 61.000EUR and the significance rating of the trade was 85/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Press Release: Sanofi completes the acquisition of Vigil Neuroscience,...
Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc. Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of (“Vigil”). This acquisition strengthens Sanofi’s early-stage pipeline in neurology with VG-3927, a novel, oral, small-molecule TREM2 agonist, which will be evaluated in a phase 2 clinical study in patients with Alzheimer’s disease. In addition, the acquisition of Vigil’s preclinical pipeline will further strengthen Sanofi’s research in various neurodegenerative diseases. In June 2024, Sanofi ...
Communiqué de presse : Sanofi finalise l’acquisition de Vigil Neurosci...
Communiqué de presse : Sanofi finalise l’acquisition de Vigil Neuroscience, Inc. Sanofi finalise l’acquisition de Vigil Neuroscience, Inc. Paris, le 6 août 2025. Sanofi annonce la finalisation de (« Vigil »). Cette acquisition renforce le pipeline de Sanofi en neurologie avec le VG-3927, un nouvel agoniste oral de TREM2, qui sera évalué dans une étude clinique de phase 2 chez des patients atteints de la maladie d’Alzheimer. En outre, l’acquisition du pipeline préclinique de Vigil renforcera la recherche de Sanofi dans diverses maladies neurodégénératives. En juin 2024, Sanofi a réalisé u...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.